China Pharma Holdings Enters Material Agreement, Reports Equity Sales
Ticker: CPHI · Form: 8-K · Filed: Dec 23, 2025 · CIK: 1106644
| Field | Detail |
|---|---|
| Company | China Pharma Holdings, Inc. (CPHI) |
| Form Type | 8-K |
| Filed Date | Dec 23, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $9.8 m, $0.001, $1.40 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-action
TL;DR
China Pharma (CPHI) inked a big deal and sold stock on 12/22/25. Watch this space.
AI Summary
On December 22, 2025, China Pharma Holdings, Inc. entered into a material definitive agreement and reported unregistered sales of equity securities. The company, formerly known as TS Electronics Inc. and Softstone Inc., is incorporated in Nevada and operates in the pharmaceutical preparations industry.
Why It Matters
This filing indicates significant corporate actions, including a new material agreement and equity transactions, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered equity sales, which can introduce financial and operational risks.
Key Players & Entities
- CHINA PHARMA HOLDINGS, INC. (company) — Registrant
- TS ELECTRONICS INC (company) — Former Company Name
- SOFTSTONE INC (company) — Former Company Name
- December 22, 2025 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by China Pharma Holdings, Inc. on December 22, 2025?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
What type of equity securities were sold in the unregistered sales reported by China Pharma Holdings, Inc.?
The filing mentions unregistered sales of equity securities, but the specific type and details of these securities are not detailed in the provided text.
What was China Pharma Holdings, Inc. previously named?
China Pharma Holdings, Inc. was formerly known as TS ELECTRONICS INC and SOFTSTONE INC.
In which state is China Pharma Holdings, Inc. incorporated?
China Pharma Holdings, Inc. is incorporated in Nevada.
What is the Standard Industrial Classification (SIC) code for China Pharma Holdings, Inc.?
The Standard Industrial Classification (SIC) code for China Pharma Holdings, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 634 words · 3 min read · ~2 pages · Grade level 11.6 · Accepted 2025-12-23 16:05:53
Key Financial Figures
- $9.8 m — ice as contemplated by the Agreement is $9.8 million, which will be paid in the form o
- $0.001 — common stock of the Company, par value $0.001 per share (the " Common Stock "), at $1
- $1.40 — 01 per share (the " Common Stock "), at $1.40 per share. Item 3.02 Unregistered Sal
Filing Documents
- ea0270909-8k_chinapharm.htm (8-K) — 25KB
- 0001213900-25-125299.txt ( ) — 188KB
- cphi-20251222.xsd (EX-101.SCH) — 3KB
- cphi-20251222_lab.xml (EX-101.LAB) — 33KB
- cphi-20251222_pre.xml (EX-101.PRE) — 22KB
- ea0270909-8k_chinapharm_htm.xml (XML) — 3KB
01
Item 1.01 Entry into a Material Definitive Agreement. On December 22, 2025, Hainan Helpson Medical & Biotechnology Co., Ltd (" Helpson "), a wholly owned subsidiary of China Pharma Holdings, Inc. (the " Company "), entered into a Technology Transfer Agreement (the " Agreement ") with Juan Zhang (the " Transferor "). The Transferor owns an invention patent of an Ipragliflozin tablets and Method for Its Preparation (the " Invention Patent "). Pursuant to the Agreement, the Transferor will transfer the ownership of the Invention Patent to Helpson. The Transferor or its designated third party shall provide relevant technical services, which include but are not limited to product research and development, writing of registration materials, registration application and other technical services. The transfer price as contemplated by the Agreement is $9.8 million, which will be paid in the form of common stock of the Company, par value $0.001 per share (the " Common Stock "), at $1.40 per share.
02
Item 3.02 Unregistered Sales of Equity Securities. The information contained in Item 1.01 of this Current Report on Form 8-K in relation to the issuance of the Company's securities mentioned above is incorporated herein by reference. The Company is to issue an aggregate of 7,000,000 restricted shares of Common Stock in connection with the technology transfer. The Company's securities mentioned above, if and when issued, will not be registered under the Securities Act as amended (the " Securities Act "), or the securities laws of any state, and are being offered and issued in reliance on the exemption from registration under the Securities Act afforded by Regulation S promulgated thereunder for the issuance of the shares to the person who is a non-U.S. person as the securities are being issued to the person through an offshore transaction which was negotiated and consummated outside the United States.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 23, 2025 CHINA PHARMA HOLDINGS, INC. By: /s/ Zhilin Li Name: Zhilin Li Title: President and Chief Executive Officer